South Korea Biologics Market Overview

Base Year: 2023

Historical Years: 2018-2023

Forecast Years: 2024-2032

Market Growth Rate: 7.06% (2024-2032)

Advances in biotechnology, as well as the high frequency of chronic diseases, are driving the South Korea biologics market. According to the latest report by IMARC Group, South Korea biologics market size is projected to exhibit a growth rate (CAGR) of 7.06% during 2024-2032.

Download sample copy of the Report: https://www.imarcgroup.com/south-korea-biologics-market/requestsample

South Korea Biologics Industry Trends and Drivers:

Advances in biotechnology, as well as the high frequency of chronic diseases, are driving the South Korea biologics market. Furthermore, the increasing demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and biosimilars, is driven by their efficacy in treating complicated disorders such as cancer, autoimmune diseases, and diabetes. Government support for the biotechnology sector, through funding, infrastructure development, and favorable regulations, is further propelling market expansion. South Korea's strong research and development (R&D) capabilities and collaboration between academia and industry have positioned the country as a global hub for biologics innovation. Moreover, the growing focus on personalized medicine is boosting the demand for biologics tailored to individual patient needs.

A key trend in the South Korea biologics market is the increasing emphasis on biosimilar development and production. In addition to this, domestic companies are capitalizing on opportunities to manufacture cost-effective biosimilars for global markets. The adoption of advanced manufacturing technologies, including cell culture and protein engineering, is enhancing production efficiency and quality. Furthermore, the expansion of contract development and manufacturing organizations (CDMOs) in South Korea is providing scalable solutions for both local and international biologics companies. Sustainability and eco-friendly practices are also gaining traction, with manufacturers exploring green bioprocessing methods. The integration of digital technologies, such as artificial intelligence (AI) and data analytics, is streamlining drug discovery and development processes. As the demand for innovative and affordable biologics grows, the South Korea biologics market is anticipated to expand further in the coming years, establishing itself as a key player in the global biotechnology landscape.

We explore the factors propelling the South Korea biologics market growth, including technological advancements, consumer behaviors, and regulatory changes.

South Korea Biologics Industry Segmentation:

The report has segmented the market into the following categories:

Source Insights:

• Microbial
• Mammalian
• Others

Product Insights:

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense, RNAi and Molecular Therapy
• Others

Disease Insights:

• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

Manufacturing Insights:

• Outsourced
• In-House

Regional Insights:

• Seoul Capital Area
• Yeongnam (Southeastern Region)
• Honam (Southwestern Region)
• Hoseo (Central Region)
• Others

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Key highlights of the Report:

• Market Performance (2018-2023)
• Market Outlook (2024-2032)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current, and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: sales@imarcgroup.com 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145